FY2024 EPS Estimates for Pliant Therapeutics, Inc. (NASDAQ:PLRX) Reduced by Leerink Partnrs

Pliant Therapeutics, Inc. (NASDAQ:PLRXFree Report) – Analysts at Leerink Partnrs dropped their FY2024 earnings estimates for Pliant Therapeutics in a report released on Monday, February 5th. Leerink Partnrs analyst T. Smith now anticipates that the company will earn ($3.38) per share for the year, down from their prior forecast of ($3.34). Leerink Partnrs currently has a “Outperform” rating on the stock. The consensus estimate for Pliant Therapeutics’ current full-year earnings is ($2.89) per share. Leerink Partnrs also issued estimates for Pliant Therapeutics’ FY2025 earnings at ($3.61) EPS, FY2026 earnings at ($4.26) EPS, FY2027 earnings at ($4.93) EPS and FY2028 earnings at ($4.87) EPS.

A number of other analysts also recently issued reports on PLRX. Needham & Company LLC lowered their price target on shares of Pliant Therapeutics from $45.00 to $38.00 and set a “buy” rating on the stock in a report on Monday, February 5th. HC Wainwright decreased their price objective on shares of Pliant Therapeutics from $52.00 to $48.00 and set a “buy” rating on the stock in a report on Monday, February 5th. Wells Fargo & Company initiated coverage on shares of Pliant Therapeutics in a report on Friday, December 8th. They set an “overweight” rating and a $41.00 price objective on the stock. Finally, Royal Bank of Canada decreased their price target on shares of Pliant Therapeutics from $54.00 to $53.00 and set an “outperform” rating on the stock in a research note on Friday, November 10th. Eleven equities research analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $48.50.

View Our Latest Research Report on Pliant Therapeutics

Pliant Therapeutics Stock Performance

Shares of NASDAQ PLRX opened at $16.93 on Thursday. The company’s fifty day moving average price is $17.07 and its 200 day moving average price is $16.33. Pliant Therapeutics has a 1 year low of $12.60 and a 1 year high of $32.47. The company has a market capitalization of $1.01 billion, a PE ratio of -6.07 and a beta of 1.19. The company has a debt-to-equity ratio of 0.02, a quick ratio of 19.50 and a current ratio of 19.50.

Pliant Therapeutics (NASDAQ:PLRXGet Free Report) last announced its quarterly earnings results on Thursday, November 9th. The company reported ($0.70) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.78) by $0.08. Pliant Therapeutics had a negative net margin of 2,872.79% and a negative return on equity of 32.50%.

Insider Buying and Selling

In other Pliant Therapeutics news, CEO Bernard Coulie sold 25,721 shares of Pliant Therapeutics stock in a transaction dated Wednesday, January 17th. The shares were sold at an average price of $17.23, for a total transaction of $443,172.83. Following the completion of the sale, the chief executive officer now directly owns 316,382 shares in the company, valued at $5,451,261.86. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. In other Pliant Therapeutics news, CEO Bernard Coulie sold 25,721 shares of Pliant Therapeutics stock in a transaction dated Wednesday, January 17th. The shares were sold at an average price of $17.23, for a total transaction of $443,172.83. Following the completion of the sale, the chief executive officer now directly owns 316,382 shares in the company, valued at $5,451,261.86. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Hans Hull sold 9,786 shares of the firm’s stock in a transaction that occurred on Wednesday, January 17th. The shares were sold at an average price of $17.23, for a total transaction of $168,612.78. Following the completion of the transaction, the insider now directly owns 185,069 shares of the company’s stock, valued at approximately $3,188,738.87. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 50,485 shares of company stock worth $869,857. Insiders own 5.60% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in PLRX. Swiss National Bank boosted its stake in shares of Pliant Therapeutics by 8.8% in the first quarter. Swiss National Bank now owns 29,800 shares of the company’s stock valued at $209,000 after purchasing an additional 2,400 shares during the period. Acadian Asset Management LLC purchased a new position in Pliant Therapeutics in the first quarter worth approximately $27,000. BlackRock Inc. lifted its stake in Pliant Therapeutics by 0.6% in the first quarter. BlackRock Inc. now owns 1,698,212 shares of the company’s stock worth $11,905,000 after acquiring an additional 10,338 shares during the last quarter. Dimensional Fund Advisors LP purchased a new position in Pliant Therapeutics in the first quarter worth approximately $95,000. Finally, Lord Abbett & CO. LLC lifted its stake in Pliant Therapeutics by 1.8% in the first quarter. Lord Abbett & CO. LLC now owns 297,034 shares of the company’s stock worth $2,082,000 after acquiring an additional 5,220 shares during the last quarter. Hedge funds and other institutional investors own 97.30% of the company’s stock.

About Pliant Therapeutics

(Get Free Report)

Pliant Therapeutics, Inc, a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase IIa trials for idiopathic pulmonary fibrosis and primary sclerosing cholangitis.

See Also

Earnings History and Estimates for Pliant Therapeutics (NASDAQ:PLRX)

Receive News & Ratings for Pliant Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pliant Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.